CovidChloroV1, Main, Corpus, bibRecord, 000C86

Drug repurposing approach to fight COVID-19.

Identifieur interne : 000C86 ( Main/Corpus ); précédent : 000C85; suivant : 000C87

Drug repurposing approach to fight COVID-19.

Auteurs : Thakur Uttam Singh ; Subhashree Parida ; Madhu Cholenahalli Lingaraju ; Manickam Kesavan ; Dinesh Kumar ; Raj Kumar Singh

Source :

Pharmacological reports : PR [ 1734-1140 ] ; 2020.

RBID : pubmed:32889701

English descriptors

KwdEn :
- Animals (MeSH), Antiviral Agents (pharmacology), Antiviral Agents (therapeutic use), COVID-19 (drug therapy), COVID-19 (virology), Computer Simulation (MeSH), Drug Discovery (methods), Drug Repositioning (MeSH), Humans (MeSH), SARS-CoV-2 (drug effects), SARS-CoV-2 (pathogenicity).
MESH :
- chemical , pharmacology : Antiviral Agents.
- chemical , therapeutic use : Antiviral Agents.
- drug effects : SARS-CoV-2.
- drug therapy : COVID-19.
- methods : Drug Discovery.
- pathogenicity : SARS-CoV-2.
- virology : COVID-19.
- Animals, Computer Simulation, Drug Repositioning, Humans.

Abstract

Currently, there are no treatment options available for the deadly contagious disease, coronavirus disease 2019 (COVID-19). Drug repurposing is a process of identifying new uses for approved or investigational drugs and it is considered as a very effective strategy for drug discovery as it involves less time and cost to find a therapeutic agent in comparison to the de novo drug discovery process. The present review will focus on the repurposing efficacy of the currently used drugs against COVID-19 and their mechanisms of action, pharmacokinetics, dosing, safety, and their future perspective. Relevant articles with experimental studies conducted in-silico, in-vitro, in-vivo, clinical trials in humans, case reports, and news archives were selected for the review. Number of drugs such as remdesivir, favipiravir, ribavirin, lopinavir, ritonavir, darunavir, arbidol, chloroquine, hydroxychloroquine, tocilizumab and interferons have shown inhibitory effects against the SARS-CoV2 in-vitro as well as in clinical conditions. These drugs either act through virus-related targets such as RNA genome, polypeptide packing and uptake pathways or target host-related pathways involving angiotensin-converting enzyme-2 (ACE2) receptors and inflammatory pathways. Using the basic knowledge of viral pathogenesis and pharmacodynamics of drugs as well as using computational tools, many drugs are currently in pipeline to be repurposed. In the current scenario, repositioning of the drugs could be considered the new avenue for the treatment of COVID-19.

DOI: 10.1007/s43440-020-00155-6
PubMed: 32889701
PubMed Central: PMC7474498

Links to Exploration step

pubmed:32889701

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Drug repurposing approach to fight COVID-19.</title>
<author><name sortKey="Singh, Thakur Uttam" sort="Singh, Thakur Uttam" uniqKey="Singh T" first="Thakur Uttam" last="Singh">Thakur Uttam Singh</name>
<affiliation><nlm:affiliation>Division of Pharmacology and Toxicology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, 243122, Uttar Pradesh, India. thakur.singh@icar.gov.in.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Parida, Subhashree" sort="Parida, Subhashree" uniqKey="Parida S" first="Subhashree" last="Parida">Subhashree Parida</name>
<affiliation><nlm:affiliation>Division of Pharmacology and Toxicology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, 243122, Uttar Pradesh, India.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lingaraju, Madhu Cholenahalli" sort="Lingaraju, Madhu Cholenahalli" uniqKey="Lingaraju M" first="Madhu Cholenahalli" last="Lingaraju">Madhu Cholenahalli Lingaraju</name>
<affiliation><nlm:affiliation>Division of Pharmacology and Toxicology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, 243122, Uttar Pradesh, India.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kesavan, Manickam" sort="Kesavan, Manickam" uniqKey="Kesavan M" first="Manickam" last="Kesavan">Manickam Kesavan</name>
<affiliation><nlm:affiliation>Division of Pharmacology and Toxicology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, 243122, Uttar Pradesh, India.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kumar, Dinesh" sort="Kumar, Dinesh" uniqKey="Kumar D" first="Dinesh" last="Kumar">Dinesh Kumar</name>
<affiliation><nlm:affiliation>Division of Pharmacology and Toxicology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, 243122, Uttar Pradesh, India.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Singh, Raj Kumar" sort="Singh, Raj Kumar" uniqKey="Singh R" first="Raj Kumar" last="Singh">Raj Kumar Singh</name>
<affiliation><nlm:affiliation>Division of Veterinary Biotechnology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, 243122, Uttar Pradesh, India.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32889701</idno>
<idno type="pmid">32889701</idno>
<idno type="doi">10.1007/s43440-020-00155-6</idno>
<idno type="pmc">PMC7474498</idno>
<idno type="wicri:Area/Main/Corpus">000C86</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000C86</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Drug repurposing approach to fight COVID-19.</title>
<author><name sortKey="Singh, Thakur Uttam" sort="Singh, Thakur Uttam" uniqKey="Singh T" first="Thakur Uttam" last="Singh">Thakur Uttam Singh</name>
<affiliation><nlm:affiliation>Division of Pharmacology and Toxicology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, 243122, Uttar Pradesh, India. thakur.singh@icar.gov.in.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Parida, Subhashree" sort="Parida, Subhashree" uniqKey="Parida S" first="Subhashree" last="Parida">Subhashree Parida</name>
<affiliation><nlm:affiliation>Division of Pharmacology and Toxicology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, 243122, Uttar Pradesh, India.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lingaraju, Madhu Cholenahalli" sort="Lingaraju, Madhu Cholenahalli" uniqKey="Lingaraju M" first="Madhu Cholenahalli" last="Lingaraju">Madhu Cholenahalli Lingaraju</name>
<affiliation><nlm:affiliation>Division of Pharmacology and Toxicology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, 243122, Uttar Pradesh, India.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kesavan, Manickam" sort="Kesavan, Manickam" uniqKey="Kesavan M" first="Manickam" last="Kesavan">Manickam Kesavan</name>
<affiliation><nlm:affiliation>Division of Pharmacology and Toxicology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, 243122, Uttar Pradesh, India.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kumar, Dinesh" sort="Kumar, Dinesh" uniqKey="Kumar D" first="Dinesh" last="Kumar">Dinesh Kumar</name>
<affiliation><nlm:affiliation>Division of Pharmacology and Toxicology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, 243122, Uttar Pradesh, India.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Singh, Raj Kumar" sort="Singh, Raj Kumar" uniqKey="Singh R" first="Raj Kumar" last="Singh">Raj Kumar Singh</name>
<affiliation><nlm:affiliation>Division of Veterinary Biotechnology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, 243122, Uttar Pradesh, India.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Pharmacological reports : PR</title>
<idno type="ISSN">1734-1140</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals (MeSH)</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>COVID-19 (drug therapy)</term>
<term>COVID-19 (virology)</term>
<term>Computer Simulation (MeSH)</term>
<term>Drug Discovery (methods)</term>
<term>Drug Repositioning (MeSH)</term>
<term>Humans (MeSH)</term>
<term>SARS-CoV-2 (drug effects)</term>
<term>SARS-CoV-2 (pathogenicity)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS-CoV-2</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Discovery</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>SARS-CoV-2</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>COVID-19</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Computer Simulation</term>
<term>Drug Repositioning</term>
<term>Humans</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Currently, there are no treatment options available for the deadly contagious disease, coronavirus disease 2019 (COVID-19). Drug repurposing is a process of identifying new uses for approved or investigational drugs and it is considered as a very effective strategy for drug discovery as it involves less time and cost to find a therapeutic agent in comparison to the de novo drug discovery process. The present review will focus on the repurposing efficacy of the currently used drugs against COVID-19 and their mechanisms of action, pharmacokinetics, dosing, safety, and their future perspective. Relevant articles with experimental studies conducted in-silico, in-vitro, in-vivo, clinical trials in humans, case reports, and news archives were selected for the review. Number of drugs such as remdesivir, favipiravir, ribavirin, lopinavir, ritonavir, darunavir, arbidol, chloroquine, hydroxychloroquine, tocilizumab and interferons have shown inhibitory effects against the SARS-CoV2 in-vitro as well as in clinical conditions. These drugs either act through virus-related targets such as RNA genome, polypeptide packing and uptake pathways or target host-related pathways involving angiotensin-converting enzyme-2 (ACE2) receptors and inflammatory pathways. Using the basic knowledge of viral pathogenesis and pharmacodynamics of drugs as well as using computational tools, many drugs are currently in pipeline to be repurposed. In the current scenario, repositioning of the drugs could be considered the new avenue for the treatment of COVID-19.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32889701</PMID>
<DateCompleted><Year>2020</Year>
<Month>12</Month>
<Day>07</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>01</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1734-1140</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>72</Volume>
<Issue>6</Issue>
<PubDate><Year>2020</Year>
<Month>Dec</Month>
</PubDate>
</JournalIssue>
<Title>Pharmacological reports : PR</Title>
<ISOAbbreviation>Pharmacol Rep</ISOAbbreviation>
</Journal>
<ArticleTitle>Drug repurposing approach to fight COVID-19.</ArticleTitle>
<Pagination><MedlinePgn>1479-1508</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s43440-020-00155-6</ELocationID>
<Abstract><AbstractText>Currently, there are no treatment options available for the deadly contagious disease, coronavirus disease 2019 (COVID-19). Drug repurposing is a process of identifying new uses for approved or investigational drugs and it is considered as a very effective strategy for drug discovery as it involves less time and cost to find a therapeutic agent in comparison to the de novo drug discovery process. The present review will focus on the repurposing efficacy of the currently used drugs against COVID-19 and their mechanisms of action, pharmacokinetics, dosing, safety, and their future perspective. Relevant articles with experimental studies conducted in-silico, in-vitro, in-vivo, clinical trials in humans, case reports, and news archives were selected for the review. Number of drugs such as remdesivir, favipiravir, ribavirin, lopinavir, ritonavir, darunavir, arbidol, chloroquine, hydroxychloroquine, tocilizumab and interferons have shown inhibitory effects against the SARS-CoV2 in-vitro as well as in clinical conditions. These drugs either act through virus-related targets such as RNA genome, polypeptide packing and uptake pathways or target host-related pathways involving angiotensin-converting enzyme-2 (ACE2) receptors and inflammatory pathways. Using the basic knowledge of viral pathogenesis and pharmacodynamics of drugs as well as using computational tools, many drugs are currently in pipeline to be repurposed. In the current scenario, repositioning of the drugs could be considered the new avenue for the treatment of COVID-19.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Singh</LastName>
<ForeName>Thakur Uttam</ForeName>
<Initials>TU</Initials>
<AffiliationInfo><Affiliation>Division of Pharmacology and Toxicology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, 243122, Uttar Pradesh, India. thakur.singh@icar.gov.in.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Parida</LastName>
<ForeName>Subhashree</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Division of Pharmacology and Toxicology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, 243122, Uttar Pradesh, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lingaraju</LastName>
<ForeName>Madhu Cholenahalli</ForeName>
<Initials>MC</Initials>
<AffiliationInfo><Affiliation>Division of Pharmacology and Toxicology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, 243122, Uttar Pradesh, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kesavan</LastName>
<ForeName>Manickam</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Division of Pharmacology and Toxicology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, 243122, Uttar Pradesh, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kumar</LastName>
<ForeName>Dinesh</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Division of Pharmacology and Toxicology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, 243122, Uttar Pradesh, India.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Singh</LastName>
<ForeName>Raj Kumar</ForeName>
<Initials>RK</Initials>
<AffiliationInfo><Affiliation>Division of Veterinary Biotechnology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, 243122, Uttar Pradesh, India.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>09</Month>
<Day>05</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Switzerland</Country>
<MedlineTA>Pharmacol Rep</MedlineTA>
<NlmUniqueID>101234999</NlmUniqueID>
<ISSNLinking>1734-1140</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003198" MajorTopicYN="N">Computer Simulation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055808" MajorTopicYN="N">Drug Discovery</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058492" MajorTopicYN="Y">Drug Repositioning</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword>
<Keyword MajorTopicYN="N">Coronavirus</Keyword>
<Keyword MajorTopicYN="N">Repurposing</Keyword>
<Keyword MajorTopicYN="N">SARS-CoV2</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>05</Month>
<Day>16</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>08</Month>
<Day>24</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>08</Month>
<Day>20</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>9</Month>
<Day>6</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>12</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>9</Month>
<Day>5</Day>
<Hour>12</Hour>
<Minute>32</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32889701</ArticleId>
<ArticleId IdType="doi">10.1007/s43440-020-00155-6</ArticleId>
<ArticleId IdType="pii">10.1007/s43440-020-00155-6</ArticleId>
<ArticleId IdType="pmc">PMC7474498</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>PLoS Negl Trop Dis. 2017 Feb 23;11(2):e0005389</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28231247</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Therapie. 2020 Apr;75(2):161-167</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32164975</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2005 Sep;19(3):216-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16261200</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Aliment Pharmacol Ther. 2004 Oct 15;20(8):825-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15479353</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ther Clin Risk Manag. 2008 Oct;4(5):1023-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19209283</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hum Genet. 2012 Dec;131(12):1811-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22825316</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2020 Mar;579(7798):270-273</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32015507</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur Respir J. 2020 Sep 24;56(3):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32631841</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Mol Sci. 2020 Apr 24;21(8):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32344526</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24841273</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2013 Apr;57(4):1743-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23357765</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Nephrol. 2020;51(5):337-342</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32222713</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Acta Pharm Sin B. 2020 May;10(5):766-788</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32292689</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2020 Jun;178:104786</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32251767</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 May 7;382(19):1787-1799</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32187464</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ophthalmology. 2015 Jan;122(1):110-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25182842</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Aug;56(2):105998</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32360231</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Microb Pathog. 2020 Nov;148:104365</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32619669</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Scand J Rheumatol. 1974;3(2):103-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">4608161</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2014 Jul;107:84-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24769245</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Viruses. 2010 Aug;2(8):1804-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21994708</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2000 Jan 5;283(1):74-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10632283</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Autoimmun Rev. 2020 Jul;19(7):102568</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32376398</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Med Res. 2020 Aug;51(6):577-581</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32387040</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 May 30;395(10238):1695-1704</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32401715</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):219-222</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32164092</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Med. 1983 Jul 18;75(1A):40-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6869410</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2015 Sep;121:132-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26186980</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 2020 Apr;92(4):455-459</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31994738</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Infect Dis. 2020 Aug;97:7-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32479865</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2009 May 10;387(2):402-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19304306</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drug Discov Ther. 2020;14(1):58-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32147628</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pathogens. 2019 Sep 12;8(3):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31547236</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Viruses. 2020 May 10;12(5):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32397643</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2018 Aug 27;62(9):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29967017</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biosci Trends. 2020 Mar 16;14(1):64-68</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32037389</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Pharmacokinet. 1996 Oct;31(4):257-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8896943</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Life Sci. 2020 Jul 1;252:117652</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32278693</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2018 May 29;92(12):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29618647</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Fundam Clin Pharmacol. 2005 Feb;19(1):117-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15660968</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Pharmacol Ther. 2020 Aug;108(2):242-247</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32246834</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antivir Ther. 2008;13(1):1-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18389894</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Transl Med. 2016 Nov;4(21):421</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27942512</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):732-739</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Rheumatol Rehabil. 1976 Aug;15(3):235-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">968356</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Transl Med. 2017 Jun 28;9(396):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28659436</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Biosyst. 2015 Jul;11(7):2096-102</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25998487</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2015 Dec 15;212(12):1904-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26198719</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect. 2020 Jul;81(1):e21-e23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32283143</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 May;55(5):105938</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32171740</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):769-777</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32176772</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chin Med J (Engl). 2020 May 5;133(9):1051-1056</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32149769</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Yao Xue Xue Bao. 2014 Nov;49(11):1547-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25757280</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Engineering (Beijing). 2020 Oct;6(10):1192-1198</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32346491</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Hepatol. 2013 Apr;58(4):792-800</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23137766</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Microbes Infect. 2020 Dec;9(1):757-760</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32228222</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Med. 1983 Jul 18;75(1A):11-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6408923</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Drug Discov. 2016 May;15(5):327-47</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26868298</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Leukemia. 2020 Jul;34(7):1805-1815</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32518419</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Med Chem. 2006;13(27):3351-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17168855</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2012 Nov 8;367(19):1814-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23075143</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 2020 Jul;92(7):814-818</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32253759</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Allergy Clin Immunol. 2020 Jul;146(1):137-146.e3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32470486</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Gastroenterol Clin Biol. 2009 Jun-Jul;33(6-7):580-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19481390</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2013 Oct;19(10):1313-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24013700</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Virol. 2005 Nov;34(3):170-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15893956</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Oncol Pharm Pract. 2014 Oct;20(5):386-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24067929</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Trials. 2018 Jan 30;19(1):81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29382391</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Pharmacol. 2017 Apr;57(4):459-468</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27599663</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Front Pharmacol. 2020 Jun 24;11:950</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32670066</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Microbiol. 2009 Mar;7(3):226-36</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19198616</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect. 2020 Jul;81(1):e1-e5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32171872</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2014 May;105:17-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24583123</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 1999 Oct;43(10):2451-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10508023</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Proteome Res. 2020 Nov 6;19(11):4690-4697</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32692185</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biosci Trends. 2020 Mar 16;14(1):69-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31996494</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 May 16;395(10236):1569-1578</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32423584</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Viruses. 2020 Feb 25;12(3):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32106567</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Ophthalmol. 1993 Oct;25(10):385-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8304691</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Biosci. 2014 Jan 13;4(1):3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24410900</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2020 Jul 3;370:m2648</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32620554</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Viruses. 2012 Jun;4(6):1011-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22816037</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chin Med J (Engl). 2020 May 5;133(9):1132-1134</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32149772</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect. 2020 Oct;81(4):647-679</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32592703</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Can J Cardiol. 2016 Jul;32(7 Suppl):S35-65</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27342697</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Hosp Pharm. 2018 May;25(3):132-137</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31157007</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Thorax. 2004 Mar;59(3):252-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14985565</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Discov. 2020 Mar 18;6:16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32194981</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>F1000Res. 2020 Feb 21;9:129</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32194944</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Wiley Interdiscip Rev Syst Biol Med. 2016 May;8(3):186-210</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27080087</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Nov 5;383(19):1827-1837</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32459919</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Drug Discov. 2019 Jan;18(1):41-58</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30310233</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Korean Med Sci. 2020 Feb 17;35(6):e79</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32056407</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>CNS Drugs. 2005;19(2):105-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15697325</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Antimicrob Chemother. 2008 Dec;62(6):1174-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18931138</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Aging (Albany NY). 2020 Mar 30;12(8):6511-6517</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32229706</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Gastroenterology. 2003 May;124(6):1711-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12761728</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biomol Struct Dyn. 2020 May 6;:1-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32338164</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 Feb 21;49(1):147-157</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32096367</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biomol Struct Dyn. 2020 Apr 13;:1-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32238094</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Mar 5;382(10):929-936</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32004427</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hum Vaccin Immunother. 2017 Sep 2;13(9):1972-1988</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28841363</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2020 Mar 17;94(7):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31996437</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Oncol. 2020 Jul;31(7):961-964</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32247642</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Opin Nephrol Hypertens. 2011 Jan;20(1):1-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21045683</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ter Arkh. 2005;77(8):84-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16206613</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drug Dev Res. 2020 Aug;81(5):541-543</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32227357</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr HIV/AIDS Rep. 2014 Sep;11(3):212-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24950731</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochim Biophys Acta. 2014 Jan;1844(1 Pt A):156-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23707564</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>FASEB J. 2008 Mar;22(3):659-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17942826</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>mBio. 2018 Mar 6;9(2):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29511076</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Public Health. 2016 May-Jun;9(3):227-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27095301</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Discov. 2020 Mar 16;6:14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32194980</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drugs. 2003;63(8):769-802</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12662125</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Discov. 2020 May 2;6:28</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32373347</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2010 Nov;84(21):11336-49</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20686038</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Biotechnol. 2006 Jul;24(7):805-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16841068</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc (Bayl Univ Med Cent). 2003 Jan;16(1):123-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16278727</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2020 Mar 24;117(12):6771-6776</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32054787</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biomol Struct Dyn. 2020 Apr 20;:1-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32266873</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2020 Apr 10;295(15):4773-4779</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32094225</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2020 Aug;547:7-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32442105</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2020 Jun;20(6):689-696</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32220650</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Pharmacokinet. 2013 Oct;52(10):815-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23703578</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>EXCLI J. 2020 Mar 17;19:400-409</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32210741</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Pathol. 2011 Dec;225(4):618-27</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22009550</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>mBio. 2020 Mar 20;11(2):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32198163</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2009 Apr;53(4):1468-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19188392</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Regul Homeost Agents. 2020 Jun 04;34(3):1241-1243</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32551464</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 2020 May;92(5):461-463</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32073161</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br J Clin Pharmacol. 2015 Apr;79(4):650-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25297637</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Apr 15;70(9):1837-1844</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31925415</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Mol Immunol. 2020 Jun;17(6):613-620</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32203189</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2005 Jul;26(1):88-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15878262</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med (N Y). 2020 Dec 18;1(1):105-113.e4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32838353</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2020 Jun;178:104787</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32251768</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>mBio. 2015 Aug 11;6(4):e01120</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26265720</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Life Sci. 2020 Jul 15;253:117592</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32222463</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virol J. 2005 Aug 22;2:69</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16115318</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2016 Mar 17;531(7594):381-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26934220</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ter Arkh. 2018 Aug 27;90(8):48-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30701939</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Virol. 2007;152(8):1447-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17497238</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2012 Jan;93(1):2-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22068147</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Trials. 2020 Jun 8;21(1):504</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32513231</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Jun 24;48(6):450-455</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32120458</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Res. 2013 Aug;23(8):986-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23835475</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Med Insights Arthritis Musculoskelet Disord. 2010 Dec 19;3:81-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21234291</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Turk J Med Sci. 2020 Apr 15;50(SI-1):611-619</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32293834</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacol Res. 2020 Jul;157:104874</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32360581</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Rev Panam Salud Publica. 2020 Mar 20;44:e40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32256547</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32350134</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Microbiol. 2020 Apr;5(4):536-544</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32123347</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Rep. 2013;3:1686</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23594967</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Rheum Dis. 2020 May;79(5):668-669</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32241792</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Antimicrob Chemother. 2005 Feb;55(2):280-1</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15650005</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunotherapy. 2020 Apr;12(5):269-273</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32212881</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Pept Sci. 2015 Jul;21(7):554-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25810135</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Chem Inf Model. 2020 Dec 28;60(12):5771-5780</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32530282</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Pharmacol. 2015 Feb 1;93(3):343-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25482567</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Rev Med Virol. 2006 Jan-Feb;16(1):37-48</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16287208</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Pharmacol. 2011;3:39-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22287855</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Apr;55(4):105944</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32179150</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 2020 Jun 24;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32579254</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 2020 Oct;92(10):2087-2095</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32374457</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Hum Hypertens. 2000 Apr;14 Suppl 1:S73-86</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10854085</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Inform. 2020 Aug;39(8):e2000028</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32162456</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Infect Dis Rep. 2020 Mar 16;12(1):8543</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32218915</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect. 2020 Aug;81(2):318-356</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32333918</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vopr Virusol. 2008 Jul-Aug;53(4):9-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18756809</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drug Discov Ther. 2020 May 6;14(2):105-106</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32213760</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Chem Inf Model. 2020 Jun 22;60(6):3277-3286</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32315171</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Hepatol. 2003;39 Suppl 1:S93-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14708685</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood Adv. 2020 Apr 14;4(7):1307-1310</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32243501</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2008 Sep;52(9):3276-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18625762</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Rheum Dis. 2009 Oct;68(10):1580-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19019888</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>mBio. 2015 Sep 29;6(5):e01303-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26419878</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Pathog. 2020 Mar 16;16(3):e1008341</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32176725</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2020 Feb 3;221(4):498-500</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31828327</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Med Chem. 2020;27(27):4542-4548</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32400323</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Nov 5;383(19):1813-1826</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32445440</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Biotechnol. 2020 Apr;38(4):379-381</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205870</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Pharmacother. 2012 May;46(5):703-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22550277</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Hypertens. 2001 Jul;14(7 Pt 2):242S-247S</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11459213</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Negl Trop Dis. 2011 Oct;5(10):e1342</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22022624</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur Respir J. 2003 May;21(5):739-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12765412</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Jun 11;382(24):2327-2336</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32275812</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2020 Apr 16;181(2):271-280.e8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32142651</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2020 May 21;64(6):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32312781</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antivir Chem Chemother. 2018 Jan-Dec;26:2040206618764483</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29562753</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Ophthalmol. 2016 Apr 18;9(4):640-2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27162744</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Jul 17;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32678530</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Enferm Infecc Microbiol Clin. 2008 Oct;26 Suppl 10:3-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19195453</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Exp Hepatol. 2012 Mar;2(1):42-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25755405</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eye (Lond). 2017 Jun;31(6):828-845</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28282061</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Genet Genomics. 2020 Feb 20;47(2):119-121</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32173287</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Invest. 1948 May;27(3 Pt 2):60-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16695637</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>World J Pediatr. 2020 Jun;16(3):219-221</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32026147</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Hepatol. 2012;2012:760706</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22506127</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Infect Dis. 2020 Jul;96:500-502</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32470602</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Pharmacokinet. 2007;46(9):739-56</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17713972</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br J Clin Pharmacol. 1986 Jul;22(1):31-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3741724</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lupus. 1996 Jun;5 Suppl 1:S11-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8803904</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2020 Apr 21;64(5):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32152082</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Front Microbiol. 2014 Jun 17;5:296</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24987391</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacol Res Perspect. 2017 Jan 23;5(1):e00293</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28596841</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Drug Saf. 2009 Sep;4(3):209-28</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19534648</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Apr 23;382(17):1653-1659</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32227760</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pediatr Crit Care Med. 2013 Nov;14(9):e438-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24226567</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Future Virol. 2011 May;6(5):615-631</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21765859</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Glob Health. 2020 Sep;8(9):e1125-e1126</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32679038</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C86 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000C86 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:32889701
   |texte=   Drug repurposing approach to fight COVID-19.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i   -Sk "pubmed:32889701" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

Drug repurposing approach to fight COVID-19.

Drug repurposing approach to fight COVID-19.

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki